A tighter archive for life-science signals.
Search once, then narrow by source or topic.
Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FDA fully releases clinical hold on Intellia CRISPR gene therapy trials
FDA fully releases clinical hold on Intellia CRISPR gene therapy trials
Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
Chutes & Ladders—Sarepta CEO to step down as DM1 hits close to home
Chutes & Ladders—Sarepta CEO to step down as DM1 hits close to home
FDA slams ExThera with warning letter over controversial blood filter device
FDA slams ExThera with warning letter over controversial blood filter device
Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing
Generate scores largest biotech IPO since 2024 with $400M Nasdaq listing
Thermo Fisher unveils test to aid in dosing of antirejection drug
Thermo Fisher unveils test to aid in dosing of antirejection drug
Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
Earendil pens $885M pact to use WuXi XDC's linker tech for next-gen ADCs
Spatial Biomarker Panels for Clinical Trials
Spatial Biomarker Panels for Clinical Trials
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
Brand directory, kept in view
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page